These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 3472675)

  • 1. Comparative metabolism and elimination of adriamycin and 4'-epiadriamycin in the rat.
    Sweatman TW; Israel M
    Cancer Chemother Pharmacol; 1987; 19(3):201-6. PubMed ID: 3472675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disposition and metabolism of adriamycin in the rat.
    Tavoloni N; Guarino AM
    Pharmacology; 1980; 21(4):244-55. PubMed ID: 7422708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacology of N,N-di(n-butyl)adriamycin-14-valerate in the rat.
    Han G; Israel M; Seshadri R; Dalton JT; Sweatman TW
    Cancer Chemother Pharmacol; 1996; 37(5):472-8. PubMed ID: 8599871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of tetrahydropyranyladriamycin (THP-ADR) and 4'-epiadriamycin (4'-epi-ADR) on lipid peroxide levels in mice.
    Sadzuka Y; Takino Y
    Chem Pharm Bull (Tokyo); 1992 May; 40(5):1329-31. PubMed ID: 1394656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bile secretory function: a determinant of adriamycin disposition.
    Tavoloni N; Guarino AM
    Arch Int Pharmacodyn Ther; 1980 Jun; 245(2):180-97. PubMed ID: 7406604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biliary and urinary excretion of adriamycin in anesthetized rats.
    Tavoloni N; Guarino AM
    Pharmacology; 1980; 20(5):256-67. PubMed ID: 7393994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of 4'-epi-doxorubicin in man.
    Weenen H; Lankelma J; Penders PG; McVie JG; ten Bokkel Huinink WW; de Planque MM; Pinedo HM
    Invest New Drugs; 1983; 1(1):59-64. PubMed ID: 6590528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Might adriamycinol contribute to adriamycin-induced cardiotoxicity?
    Del Tacca M; Danesi R; Ducci M; Bernardini C; Romanini A
    Pharmacol Res Commun; 1985 Nov; 17(11):1073-84. PubMed ID: 4089011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative cardiotoxicity and antitumour activity of doxorubicin (adriamycin) and 4'-deoxydoxorubicin and the relationship to in vivo disposition and metabolism in the target tissues.
    Cummings J; Willmott N; More I; Kerr DJ; Morrison JG; Kaye SB
    Biochem Pharmacol; 1987 May; 36(9):1521-6. PubMed ID: 3579988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disposition of 14C-labelled 4'-epidoxorubicin and doxorubicin in the rat. A comparative study.
    Arcamone F; Lazzati M; Vicario GP; Zini G
    Cancer Chemother Pharmacol; 1984; 12(3):157-66. PubMed ID: 6584234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 4'-epi-doxorubicin, a new analogue of doxorubicin: a preliminary overview of preclinical and clinical data.
    Ganzina F
    Cancer Treat Rev; 1983 Mar; 10(1):1-22. PubMed ID: 6342772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bilary disposition of adriamycin.
    Riggs CE; Benjamin RS; Serpick AA; Bachur NR
    Clin Pharmacol Ther; 1977 Aug; 22(2):234-41. PubMed ID: 884924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Intra-arterial infusion chemotherapy of advanced breast cancer--effects and side effects of adriamycin, 4'-epi-adriamycin and THP-adriamycin].
    Toda K; Asaishi K; Okazaki M; Okazaki Y; Okazaki A; Sato H; Mikami T; Watanabe Y; Hayasaka H; Narimatsu E
    Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 2):3011-4. PubMed ID: 2782905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of aldo-keto reductases by phenobarbital alters metabolism, pharmacokinetics and toxicity of doxorubicin in rats.
    Behnia K; Boroujerdi M
    J Pharm Pharmacol; 1999 Nov; 51(11):1275-82. PubMed ID: 10632085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of route administration and liposome entrapment on the metabolism and disposition of adriamycin in the rat.
    Parker RJ; Priester ER; Sieber SM
    Drug Metab Dispos; 1982; 10(5):499-504. PubMed ID: 6128200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigation of the enterohepatic recirculation of Adriamycin and its metabolites by a linked-rat model.
    Behnia K; Boroujerdi M
    Cancer Chemother Pharmacol; 1998; 41(5):370-6. PubMed ID: 9523732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contradistinction between doxorubicin and epirubicin: in-vivo metabolism, pharmacokinetics and toxicodynamics after single- and multiple-dosing in rats.
    Ramanathan-Girish S; Boroujerdi M
    J Pharm Pharmacol; 2001 Jul; 53(7):987-97. PubMed ID: 11480551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effects of 4'-Epi-adriamycin, THP-adriamycin and mitoxantrone on patients with advanced and recurrent breast cancer].
    Tominaga T; Kitamura M; Hayashi K; Takahashi I; Kosaki G
    Gan To Kagaku Ryoho; 1984 Aug; 11(8):1669-74. PubMed ID: 6591857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Doxorubicin and doxorubicinol pharmacokinetics and tissue concentrations following bolus injection and continuous infusion of doxorubicin in the rabbit.
    Cusack BJ; Young SP; Driskell J; Olson RD
    Cancer Chemother Pharmacol; 1993; 32(1):53-8. PubMed ID: 8462124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nuclear targeting and nuclear retention of anthracycline-formaldehyde conjugates implicates DNA covalent bonding in the cytotoxic mechanism of anthracyclines.
    Taatjes DJ; Fenick DJ; Koch TH
    Chem Res Toxicol; 1999 Jul; 12(7):588-96. PubMed ID: 10409398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.